Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The pivotal trials demonstrated significant efficacy of aceclidine compared to brimonidine and vehicle, with responder rates of 65% and 71% respectively (p<0.01). However, the comparators used in the trials do not represent the standard of care for presbyopia, which typically includes corrective lenses and other pharmacologic treatments. Therefore, while the evidence shows comparable efficacy, it lacks direct relevance to real-world treatment options.
Cost effectiveness
There is no cost-utility model, incremental cost-effectiveness ratio (ICER), or QALY outcomes reported in the FDA label or other sources. The lack of economic data prevents any assessment of cost-effectiveness, making it impossible to evaluate the therapy’s value relative to its costs.
Quality of life
No validated HRQoL instruments or utility values were reported in the FDA label or other reviewed sources. The absence of any data on patient-reported outcomes or quality of life measures is a significant limitation, indicating a lack of evidence regarding the treatment’s impact on patients’ daily functioning and overall well-being.
Supporting Domains
Safety and Adverse Effects
The FDA label provides detailed information on common adverse reactions, with instillation site irritation at 20% and dim vision at 16%. The safety profile appears acceptable, with no severe adverse events reported. However, the long-term safety data is limited, creating some uncertainty about the treatment’s safety over extended use.
Comparator Selection
The comparators used in the pivotal trials (brimonidine and vehicle) do not align with the standard of care for presbyopia, which typically includes corrective lenses and other pharmacologic treatments. This limits the relevance of the trial results to real-world clinical practice, as the evidence does not directly compare aceclidine to the most commonly used treatments.
Patient Population and Subgroups
The trials included a diverse population aged 45-75 with a range of refractive errors and included post-refractive surgery patients. This broad inclusion enhances the generalizability of the findings to the intended patient population, although subgroup analyses were not reported.
Care Pathway Integration
The treatment can be integrated into existing care pathways with minimal disruption, as it involves standard ophthalmic assessments and self-administration. However, the requirement for refrigerated storage may pose some logistical challenges.
Resource Use and Cost Implications
While the operational requirements for the treatment are clearly described, including storage and administration, there is no quantification of costs associated with implementation or potential savings from avoided events. This limits the ability to assess the broader resource implications.
Evidence Quality and Robustness
The evidence is based on two randomized, double-masked controlled Phase 3 trials, which generally meet the expectations for robustness. However, there are gaps in methodological details and inconsistencies in reported safety data, which introduce some uncertainty.
Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term efficacy and safety of aceclidine, particularly beyond the trial duration of 42 days. The absence of economic sensitivity analyses further complicates the assessment of broader impacts.
